Stockscreener 앱 받기
27.87
1.87%
-0.53
전일 마감가:
$28.40
열려 있는:
$28.5
하루 거래량:
2.19M
Relative Volume:
0.98
시가총액:
$2.49B
수익:
$333.87M
순이익/손실:
$-169.00M
주가수익비율:
-13.66
EPS:
-2.04
순현금흐름:
$-157.30M
1주 성능:
-19.40%
1개월 성능:
-22.26%
6개월 성능:
+67.29%
1년 성능:
+50.89%
1일 변동 폭
$27.77
$29.31
1주일 범위
$22.59
$34.56
52주 변동 폭
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
27.87 | 2.54B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics : Investor Fact Sheet - marketscreener.com
Rate Hike: Is Travere Therapeutics Inc stock heavily shortedMarket Trend Review & Low Risk Entry Point Guides - baoquankhu1.vn
Chipmakers Recap: Whats the MACD signal for Travere Therapeutics IncMarket Activity Report & Technical Confirmation Alerts - baoquankhu1.vn
Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses - TradingView — Track All Markets
First Week of September 18th Options Trading For Travere Therapeutics (TVTX) - Nasdaq
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - FinancialContent
Two Biotechs to Play in Uncertain Times - TheStreet Pro
Travere plummets as FDA extends Filspari review for rare kidney disorder - MSN
Equities Analysts Issue Forecasts for TVTX FY2030 Earnings - MarketBeat
Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential - Seeking Alpha
Why Did TVTX Stock Crash 30% In Pre-Market Today? - Stocktwits
Travere, Ligand hammered on a surprise delay for their linchpin drug - MSN
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Is Travere Therapeutics (TVTX) Pricing Reflect Long Term Value After Recent Share Price Pullback - Yahoo Finance
Travere Therapeutics (TVTX) Is Down 18.7% After FDA Extends FILSPARI FSGS Review Timeline – Has The Bull Case Changed? - Yahoo Finance
INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC - GlobeNewswire
(TVTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Travere stock rises as FDA extends Filspari review timeline - Investing.com
Travere stock rises as FDA extends Filspari review timeline By Investing.com - Investing.com UK
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
US FDA extends review of Travere’s drug for rare kidney disease - WHTC
Biggest stock movers Wednesday: INTC, WRD, TVTX, and more (RIVN:NASDAQ) - Seeking Alpha
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere Therapeutics (TVTX) Suffers Significant Decline - GuruFocus
FDA extends review timeline for Travere’s FSGS drug application By Investing.com - Investing.com Nigeria
Why Travere Therapeutics Stock Got Trounced on Tuesday - Yahoo Finance
TVTX ALERT: Investigation Launched into Travere - GlobeNewswire
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire Inc.
Travere Therapeutics provides corporate update and 2026 outlook - MSN
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS - FinancialContent
FDA Extends Review Timeline for Travere’s FILSPARI sNDA - TipRanks
Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug - Investor's Business Daily
Travere Therapeutics FDA Review Extension for FILSPARI - TradingView — Track All Markets
FDA pushes back Travere Therapeutics (NASDAQ: TVTX) FILSPARI FSGS decision date - Stock Titan
Travere shares fall as US FDA extends review of rare kidney disease drug - Reuters
FDA Extends Review of Travere Therapeutics' Filspari sNDA - GuruFocus
Leerink says Travere’s Filspari PDUFA extension removes worst case scenario - TipRanks
SHAREHOLDER ALERT: Travere Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Should Contact The Firm - GlobeNewswire
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval - Stocktwits
Travere Therapeutics (TVTX) Faces FDA Review Delay, Shares Drop 20% - GuruFocus
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13 - TechStock²
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April - TechStock²
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April - Asianet Newsable
Travere Therapeutics Says FDA Extends Review of Filspari to April; Shares Fall - marketscreener.com
Travere Therapeutics Shares Fall After FDA Extends Filspari Review - marketscreener.com
Travere Therapeutics (TVTX) Sees FDA Review Extension for FILSPA - GuruFocus
Travere Therapeutics (TVTX) Sees FDA Review Extension for FILSPARI - GuruFocus
FDA extends review timeline for Travere’s FSGS drug application - Investing.com India
Travere Therapeutics (NASDAQ:TVTX) Shares Gap DownHere's What Happened - MarketBeat
US FDA extends review of Travere's drug for rare kidney disease - marketscreener.com
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Travere Therapeutics Inc 주식 (TVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Inrig Jula | CHIEF MEDICAL OFFICER |
Jan 06 '26 |
Sale |
37.75 |
445 |
16,799 |
86,311 |
4.73%
0.92%
자본화:
|
볼륨(24시간):